Liminatus Pharma Inc. Submits Beneficial Ownership Statement

Summary

Liminatus Pharma Inc. has filed a preliminary beneficial ownership statement indicating that KH Feelux Co., Ltd is a 10% shareholder. This information was made available through the U.S. Securities and Exchange Commission’s EDGAR system. The news was generated by Public Technologies and is for reference only, not to be considered financial or legal advice.Reuters

Impact Analysis

The event is classified at the company level as it pertains to a change in the ownership structure of Liminatus Pharma Inc. The new shareholder, KH Feelux Co., Ltd., owning 10% of the company, could have strategic implications. It may lead to better corporate governance or potential strategic partnerships in the future. This development could be viewed positively by investors, especially in the context of Liminatus Pharma’s recent advancements, such as the CD47 checkpoint inhibitor IBA101 entering human trials in the U.S. and Korea, suggesting active growth and research initiatives by the company.Reuters The ownership change may lead to increased confidence among investors, potentially stabilizing or boosting the stock price, especially following the previous significant price increase of 93.55%.LB Select Investors should watch for any announcements from KH Feelux that might indicate their strategy or direction for their stake in Liminatus Pharma.